156 related articles for article (PubMed ID: 24225757)
1. Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks.
Godfrey CC; Michelow PM; Godard M; Sahasrabuddhe VV; Darden J; Firnhaber CS; Wetherall NT; Bremer J; Coombs RW; Wilkin T;
Am J Clin Pathol; 2013 Dec; 140(6):881-9. PubMed ID: 24225757
[TBL] [Abstract][Full Text] [Related]
2. The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies.
Cubie HA; Moore C; Waller M; Moss S;
J Clin Virol; 2005 Aug; 33(4):287-92. PubMed ID: 16036178
[TBL] [Abstract][Full Text] [Related]
3. HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance.
Carozzi FM; Del Mistro A; Cuschieri K; Frayle H; Sani C; Burroni E
J Clin Virol; 2016 Mar; 76 Suppl 1():S22-S28. PubMed ID: 26669512
[TBL] [Abstract][Full Text] [Related]
4. Development of a pilot proficiency program for human papillomavirus DNA detection.
Costa AG; Escott R; Garland SM; Byers D; Tabrizi SN
Pathology; 2018 Oct; 50(6):659-664. PubMed ID: 30139535
[TBL] [Abstract][Full Text] [Related]
5. External quality assessment in gynaecological cytology: The Trent Region experience. The Trent Regional Gynaecological Pathology Quality Assurance Group for the National Health Service Cervical Screening Programme.
Slater DN; Hewer EM; Melling SE; Rice S
Cytopathology; 2002 Aug; 13(4):206-19. PubMed ID: 12269893
[TBL] [Abstract][Full Text] [Related]
6. Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study.
Engesæter B; van Diermen Hidle B; Hansen M; Moltu P; Staby KM; Borchgrevink-Persen S; Vintermyr OK; Lönnberg S; Nygård M; Janssen EA; Castle PE; Christiansen IK
BMC Infect Dis; 2016 Nov; 16(1):698. PubMed ID: 27881082
[TBL] [Abstract][Full Text] [Related]
7. Quality assurance in cervical cancer screening: results of a proficiency testing scheme for cytology laboratories in the north west Thames region.
Gifford C; Coleman DV
Cytopathology; 1994 Aug; 5(4):197-206. PubMed ID: 7948755
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus testing as part of the renewed National Cervical Screening Program.
Hawkes D
Aust J Gen Pract; 2018 Jul; 47(7):412-414. PubMed ID: 30114869
[TBL] [Abstract][Full Text] [Related]
9. Quality assurance of human papillomavirus testing.
Tachezy R; Smahelová J
Coll Antropol; 2007 Apr; 31 Suppl 2():61-5. PubMed ID: 17600935
[TBL] [Abstract][Full Text] [Related]
10. Quality assessment for human papillomavirus testing.
Tabrizi SN
Sex Health; 2010 Sep; 7(3):335-7. PubMed ID: 20719224
[TBL] [Abstract][Full Text] [Related]
11. Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China's largest independent operator of pathology laboratories.
Xie F; Zhang L; Zhao D; Wu X; Wei M; Zhang X; Wu X; Fang H; Xu X; Yang M; Qi D
BMC Infect Dis; 2019 Nov; 19(1):962. PubMed ID: 31711435
[TBL] [Abstract][Full Text] [Related]
12. External quality assessment (EQA) and alternative assessment procedures (AAPs) in molecular diagnostics: findings of an international survey.
Payne DA; Russomando G; Linder MW; Baluchova K; Ashavaid T; Steimer W; Ahmad-Nejad P;
Clin Chem Lab Med; 2020 May; 59(2):301-306. PubMed ID: 32383687
[TBL] [Abstract][Full Text] [Related]
13. The International Human Papillomavirus Reference Center: Standardization, collaboration, and quality assurance in HPV research and diagnostics.
Arroyo Mühr LS; Lagheden C; Hassan SS; Eklund C; Dillner J
J Med Virol; 2023 Dec; 95(12):e29332. PubMed ID: 38115556
[TBL] [Abstract][Full Text] [Related]
14. External quality assessment for human papillomavirus 16/18 DNA detection and genotyping in Shanghai, China.
Wang X; Liu F; Jiang L; Bao Y; Xiao Y; Wang H
Clin Chem Lab Med; 2017 Feb; 55(2):195-202. PubMed ID: 27816947
[TBL] [Abstract][Full Text] [Related]
15. Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom.
Scott DR; Hagmar B; Maddox P; Hjerpe A; Dillner J; Cuzick J; Sherman ME; Stoler MH; Kurman RJ; Kiviat NB; Manos MM; Schiffman M
Cancer; 2002 Feb; 96(1):14-20. PubMed ID: 11836698
[TBL] [Abstract][Full Text] [Related]
16. Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Akbari A; Vanden Broeck D; Benoy I; Padalko E; Bogers J; Arbyn M
Virol J; 2018 Oct; 15(1):166. PubMed ID: 30373616
[TBL] [Abstract][Full Text] [Related]
17. External quality assurance performance of clinical research laboratories in sub-saharan Africa.
Amukele TK; Michael K; Hanes M; Miller RE; Jackson JB
Am J Clin Pathol; 2012 Nov; 138(5):720-3. PubMed ID: 23086773
[TBL] [Abstract][Full Text] [Related]
18. Bethesda 2014 Implementation and Human Papillomavirus Primary Screening: Practices of Laboratories Participating in the College of American Pathologists PAP Education Program.
Davey DD; Souers RJ; Goodrich K; Mody DR; Tabbara SO; Booth CN
Arch Pathol Lab Med; 2019 Oct; 143(10):1196-1202. PubMed ID: 31021657
[TBL] [Abstract][Full Text] [Related]
19. The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing.
Eklund C; Mühr LSA; Lagheden C; Forslund O; Robertsson KD; Dillner J
J Clin Virol; 2021 Aug; 141():104902. PubMed ID: 34186414
[TBL] [Abstract][Full Text] [Related]
20. A peer comparison program for the quality assurance of human papillomavirus DNA detection using the Digene Hybrid Capture II/SurePath method shows excellent analytic interlaboratory correlation.
Kuebler DL; Illingworth A; Blenc AM; Wilbur DC
Cancer; 2007 Oct; 111(5):339-43. PubMed ID: 17879373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
